Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide - Draeger, K E; Wernicke-Panten, K; Lomp, H -J; Schüler, E; Roßkamp, R (Hormone and Metabolic Research, 1996)